Immunocellular Thera (IMUC) 0.48 $IMUC
ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program
PR Newswire - Thu Nov 12, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Dr. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, as well as Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research, at MD Anderson.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Announces Third Quarter 2015 Financial Results
PR Newswire - Tue Nov 10, 3:05PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the third quarter 2015.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics to Report Third Quarter 2015 Financial Results on November 10, 2015
PR Newswire - Tue Oct 27, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report financial results for the third quarter 2015 on Tuesday, November 10, 2015. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO.
IMUC: 0.48 (+0.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.27 (+0.12), BIIB: 280.14 (-3.39), NWBO: 4.44 (+0.01), CVM: 0.47 (-0.01), CLDX: 14.73 (+0.24), MACK: 8.48 (-0.10), INO: 6.82 (-0.12), NLNK: 35.26 (-0.74), JUNO: 52.57 (-0.90), GALE: 1.47 (unch), IMMU: 3.02 (-0.06), ADXS: 12.00 (-0.38), ADRO: 28.65 (+1.02), IMGN: 12.22 (+0.52), AMGN: 157.62 (+3.12), SPPI: 5.22 (+0.07), LLY: 81.08 (-0.15), BMY: 65.56 (+0.54), GSK: 40.54 (+0.31), SRNE: 7.88 (-0.37), ONTY: 3.30 (-0.05), IMUC: 0.48 (+0.03), PGNX: 6.49 (-0.09), ARGS: 3.95 (-0.08), GBIM: 2.41 (+0.09), BLCM: 20.51 (-0.22), SGEN: 45.30 (+1.53), KITE: 79.86 (+0.52), MRK: 53.66 (-0.04)
ImmunoCellular Therapeutics Down 11.9%, Shares Slide into the Red (IMUC)
Comtex SmarTrend(R) - Fri Sep 25, 10:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 11.9% to $0.48 on 2.6x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.6 million shares, vs. average volume of 609,000 shares per day. The stock has underperformed the Dow (-11.9% to the Dow's 1.2%) and underperformed the S&P 500 (-11.9% to the S&P's 0.8%) during today's trading.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma
PR Newswire - Thu Sep 24, 12:51PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $19.9 million to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma. The $19.9 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for grant consideration on the basis of being specifically engineered as an immunotherapy that preferentially targets and kills cancer tumor stem cells with the goal of preventing tumor recurrence following standard-of-care treatment.
IMUC: 0.48 (+0.03)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.82 (-0.12), NWBO: 4.44 (+0.01), MRK: 53.66 (-0.04), CLDX: 14.73 (+0.24), NLNK: 35.26 (-0.74), GALE: 1.47 (unch), GSK: 40.54 (+0.31), IMUC: 0.48 (+0.03), NVS: 87.42 (+0.37)
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
PR Newswire - Tue Sep 22, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that its Board of Directors has appointed Mark A. Schlossberg and Gregg A. Lapointe as Board members.
IMUC: 0.48 (+0.03)
Global Vaccine Partnering 2010-2015: Deal Trends, Players and Financials
M2 - Mon Sep 14, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw9tcf/global_vaccine) has announced the addition of the "Global Vaccine Partnering 2010-2015: Deal trends, players and financials" report to their offering. The Global Vaccine Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains a comprehensive listing of all vaccine partnering deals announced since January 2009, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Global Vaccine Partnering 2010-2015 includes: - Trends in vaccine dealmaking in the biopharma industry since 2010 - Analysis of vaccine deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life vaccine deals - Access to over 800 vaccine deal documents - The leading vaccine deals by value since 2010 - Most active vaccine dealmakers since 2010 - The leading vaccine partnering resources In Global Vaccine Partnering 2010-2015, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Therapy target - Specific technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in vaccine dealmaking Chapter 3 - Average financial deal terms for vaccine partnering Chapter 4 - Leading vaccine deals Chapter 5 - Vaccine contracts dealmaking directory Chapter 6 - Vaccine dealmaking directory by technology type Chapter 7 - Vaccine partnering resource center Companies Mentioned - 34 of the 100 Companies Featured - Abbott - AVI Pharma - Avimex - Dana-Farber Cancer Institute - Defense Threat Reduction Agency - Dendreon - Department of Health and Human Services - GlaxoSmithKline - GlaxoSmithKline Biologicals - GlobeImmune - Gynecologic Oncology Group - Heat Biologics - Henry Schein - Hollister-Stier Labs - IBioPharma - ID Biomedical - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - Isconova - ISSI-Strategy - Janssen Alzheimer Immunotherapy - Janssen Pharmaceutica NV - Johnson & Johnson - Kirin Pharma - Kyowa Hakko Kirin - LG Life Sciences - Lundbeck - Maxygen - Ohio State University - Omnimmune - OncoSec Medical - Ortho-McNeil - Otsuka - Xencor For more information visit http://www.researchandmarkets.com/research/xw...al_vaccine
HTBX: 3.27 (+0.12), JNJ: 101.27 (+0.05), INO: 6.82 (-0.12), ONCS: 3.14 (-0.05), GSK: 40.54 (+0.31), IMUC: 0.48 (+0.03), HSIC: 153.74 (-0.28)
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
PR Newswire - Fri Aug 21, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today issued the following letter to shareholders.
IMUC: 0.48 (+0.03)
Stock to Watch: ImmunoCellular Therapeutics Down 6.4% (IMUC)
Comtex SmarTrend(R) - Wed Aug 19, 11:44AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 6.4% to $0.41 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 579,000 shares thus far today, vs. average volume of 544,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.0%) and underperformed the S&P 500 (-6.4% to the S&P's -0.9%) during today's trading.
IMUC: 0.48 (+0.03)
Hot Stock: ImmunoCellular Therapeutics, Shares Gain 20.7% (IMUC)
Comtex SmarTrend(R) - Thu Aug 13, 10:38AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 20.7% to $0.53 on 14.9x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 4.5 million shares, vs. average volume of 302,000 shares per day. The stock has outperformed the Dow (20.7% to the Dow's -0.2%) and outperformed the S&P 500 (20.7% to the S&P's -0.2%) during today's trading.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
PR Newswire - Thu Aug 13, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) announced today that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary endpoint in the trial is overall survival, which the FDA and EU regulators have stated is the appropriate endpoint for registrational clinical studies in glioblastoma. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups. Patient enrollment is anticipated to begin in the late third quarter or early fourth quarter of 2015.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
PR Newswire - Thu Aug 06, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the second quarter 2015.
IMUC: 0.48 (+0.03)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 3.02 (-0.06), CERU: 3.03 (-0.27), AMGN: 157.62 (+3.12), LLY: 81.08 (-0.15), BIND: 4.70 (-0.05), GSK: 40.54 (+0.31), BMY: 65.56 (+0.54), IMUC: 0.48 (+0.03), AZN: 33.33 (+0.55), CYTR: 3.07 (-0.06), AVEO: 1.14 (-0.02), ABBV: 60.17 (+0.16), EXEL: 5.60 (+0.12), ARRY: 4.20 (-0.06)
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
PR Newswire - Thu Jul 23, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the second quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO.
IMUC: 0.48 (+0.03)
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 6.2% (IMUC)
Comtex SmarTrend(R) - Wed Jul 15, 10:42AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 6.2% to $0.51 on 1.2x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 489,000 shares, vs. average volume of 423,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.1%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
IMUC: 0.48 (+0.03)
Active Equities to Watch in the Biotechnology Industry -- Prima Biomed, Oncothyreon, Opko Health, ImmunoCellular Therapeutics, and Adaptimmune Therapeutics
PR Newswire - Wed Jul 15, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). Free research report on Prima Biomed can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PBMD On Tuesday, July 14, 2015, the NASDAQ Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial Average advanced 0.42%, to finish the day at 18,053.58, and the S&P 500 closed at 2,108.95, up 0.45%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PBMD: 1.12 (-0.02), OPK: 10.74 (+0.11), ADAP: 9.78 (+0.26), IMUC: 0.48 (+0.03), ONTY: 3.30 (-0.05)
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
PR Newswire - Mon Jul 06, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. The ICT-107 phase 3 trial will include approximately 120 clinical sites in the US, Europe and Canada, and will recruit about 400 patients with newly diagnosed glioblastoma. ImmunoCellular anticipates initiating the phase 3 trial in the fourth quarter of 2015.
IMUC: 0.48 (+0.03)
Global Cancer Vaccines Market 2015-2019 with Dendreon, GSK & Merck Dominating
M2 - Tue Jun 30, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wtt7gg/global_cancer) has announced the addition of the "Global Cancer Vaccines Market 2015-2019" report to their offering. The global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019. Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines. Strategic alliances not only help a vendor increase its market penetration but they also enhance the vendor's product portfolio. For instance, GAVI Alliance aims to immunize about 2-million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are supplied at a low cost by GlaxoSmithKline and Merck. In 2015, Bristol-Myers Squibb collaborated with Bavarian Nordic to develop Prostvac, a therapeutic vaccine for the treatment of prostate cancer. Together, in 2015, Advaxis and Incyte evaluated ADXS-HPV using Incyte's investigational oral indoleamine 2,3-dioxygenase 1 inhibitor, epacadostat. In 2014, Boehringer Ingelheim and CureVac entered into an agreement to develop and commercialize a lung cancer vaccine CV9202 using CureVac's RNA technology, RNActive. According to the report, cancer is a leading cause of deaths worldwide. According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers. Further, the report states that cold chain, or temperature-controlled supply chain, management is a major challenge for this market. Key Vendors - Dendreon - GlaxoSmithKline - Merck Other Prominent Vendors - Aduro BioTech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Amgen - Antigen Express - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Bristol-Myers Squibb - Cytos - Galena Biopharma - Genexine - GlobeImmune - ImmunoCellular Therapeutics - Immutep - Inovio Pharmaceuticals - Isa Pharmaceuticals - Juvaris Biotherapeutics - MedImmune - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Progenics - Provectus Biopharmaceuticals - Sanofi - Sotio - Transgene - Ubivac For more information visit http://www.researchandmarkets.com/research/wt...bal_cancer
PVCT: 0.46 (-0.03), INO: 6.82 (-0.12), ARGS: 3.95 (-0.08), NWBO: 4.44 (+0.01), ADRO: 28.65 (+1.02), MRK: 53.66 (-0.04), NLNK: 35.26 (-0.74), AMGN: 157.62 (+3.12), GALE: 1.47 (unch), GSK: 40.54 (+0.31), BMY: 65.56 (+0.54), IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program
PR Newswire - Thu Nov 12, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Dr. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, as well as Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research, at MD Anderson. IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Announces Third Quarter 2015 Financial Results
PR Newswire - Tue Nov 10, 3:05PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the third quarter 2015. IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics to Report Third Quarter 2015 Financial Results on November 10, 2015
PR Newswire - Tue Oct 27, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report financial results for the third quarter 2015 on Tuesday, November 10, 2015. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO. IMUC: 0.48 (+0.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.27 (+0.12), BIIB: 280.14 (-3.39), NWBO: 4.44 (+0.01), CVM: 0.47 (-0.01), CLDX: 14.73 (+0.24), MACK: 8.48 (-0.10), INO: 6.82 (-0.12), NLNK: 35.26 (-0.74), JUNO: 52.57 (-0.90), GALE: 1.47 (unch), IMMU: 3.02 (-0.06), ADXS: 12.00 (-0.38), ADRO: 28.65 (+1.02), IMGN: 12.22 (+0.52), AMGN: 157.62 (+3.12), SPPI: 5.22 (+0.07), LLY: 81.08 (-0.15), BMY: 65.56 (+0.54), GSK: 40.54 (+0.31), SRNE: 7.88 (-0.37), ONTY: 3.30 (-0.05), IMUC: 0.48 (+0.03), PGNX: 6.49 (-0.09), ARGS: 3.95 (-0.08), GBIM: 2.41 (+0.09), BLCM: 20.51 (-0.22), SGEN: 45.30 (+1.53), KITE: 79.86 (+0.52), MRK: 53.66 (-0.04)
ImmunoCellular Therapeutics Down 11.9%, Shares Slide into the Red (IMUC)
Comtex SmarTrend(R) - Fri Sep 25, 10:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 11.9% to $0.48 on 2.6x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.6 million shares, vs. average volume of 609,000 shares per day. The stock has underperformed the Dow (-11.9% to the Dow's 1.2%) and underperformed the S&P 500 (-11.9% to the S&P's 0.8%) during today's trading.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma
PR Newswire - Thu Sep 24, 12:51PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $19.9 million to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma. The $19.9 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for grant consideration on the basis of being specifically engineered as an immunotherapy that preferentially targets and kills cancer tumor stem cells with the goal of preventing tumor recurrence following standard-of-care treatment. IMUC: 0.48 (+0.03)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.82 (-0.12), NWBO: 4.44 (+0.01), MRK: 53.66 (-0.04), CLDX: 14.73 (+0.24), NLNK: 35.26 (-0.74), GALE: 1.47 (unch), GSK: 40.54 (+0.31), IMUC: 0.48 (+0.03), NVS: 87.42 (+0.37)
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
PR Newswire - Tue Sep 22, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that its Board of Directors has appointed Mark A. Schlossberg and Gregg A. Lapointe as Board members. IMUC: 0.48 (+0.03)
Global Vaccine Partnering 2010-2015: Deal Trends, Players and Financials
M2 - Mon Sep 14, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw9tcf/global_vaccine) has announced the addition of the "Global Vaccine Partnering 2010-2015: Deal trends, players and financials" report to their offering. The Global Vaccine Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains a comprehensive listing of all vaccine partnering deals announced since January 2009, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Global Vaccine Partnering 2010-2015 includes: - Trends in vaccine dealmaking in the biopharma industry since 2010 - Analysis of vaccine deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life vaccine deals - Access to over 800 vaccine deal documents - The leading vaccine deals by value since 2010 - Most active vaccine dealmakers since 2010 - The leading vaccine partnering resources In Global Vaccine Partnering 2010-2015, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Therapy target - Specific technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in vaccine dealmaking Chapter 3 - Average financial deal terms for vaccine partnering Chapter 4 - Leading vaccine deals Chapter 5 - Vaccine contracts dealmaking directory Chapter 6 - Vaccine dealmaking directory by technology type Chapter 7 - Vaccine partnering resource center Companies Mentioned - 34 of the 100 Companies Featured - Abbott - AVI Pharma - Avimex - Dana-Farber Cancer Institute - Defense Threat Reduction Agency - Dendreon - Department of Health and Human Services - GlaxoSmithKline - GlaxoSmithKline Biologicals - GlobeImmune - Gynecologic Oncology Group - Heat Biologics - Henry Schein - Hollister-Stier Labs - IBioPharma - ID Biomedical - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - Isconova - ISSI-Strategy - Janssen Alzheimer Immunotherapy - Janssen Pharmaceutica NV - Johnson & Johnson - Kirin Pharma - Kyowa Hakko Kirin - LG Life Sciences - Lundbeck - Maxygen - Ohio State University - Omnimmune - OncoSec Medical - Ortho-McNeil - Otsuka - Xencor For more information visit http://www.researchandmarkets.com/research/xw...al_vaccine
HTBX: 3.27 (+0.12), JNJ: 101.27 (+0.05), INO: 6.82 (-0.12), ONCS: 3.14 (-0.05), GSK: 40.54 (+0.31), IMUC: 0.48 (+0.03), HSIC: 153.74 (-0.28)
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
PR Newswire - Fri Aug 21, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today issued the following letter to shareholders. IMUC: 0.48 (+0.03)
Stock to Watch: ImmunoCellular Therapeutics Down 6.4% (IMUC)
Comtex SmarTrend(R) - Wed Aug 19, 11:44AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 6.4% to $0.41 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 579,000 shares thus far today, vs. average volume of 544,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.0%) and underperformed the S&P 500 (-6.4% to the S&P's -0.9%) during today's trading.
IMUC: 0.48 (+0.03)
Hot Stock: ImmunoCellular Therapeutics, Shares Gain 20.7% (IMUC)
Comtex SmarTrend(R) - Thu Aug 13, 10:38AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 20.7% to $0.53 on 14.9x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 4.5 million shares, vs. average volume of 302,000 shares per day. The stock has outperformed the Dow (20.7% to the Dow's -0.2%) and outperformed the S&P 500 (20.7% to the S&P's -0.2%) during today's trading.
IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
PR Newswire - Thu Aug 13, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) announced today that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary endpoint in the trial is overall survival, which the FDA and EU regulators have stated is the appropriate endpoint for registrational clinical studies in glioblastoma. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups. Patient enrollment is anticipated to begin in the late third quarter or early fourth quarter of 2015. IMUC: 0.48 (+0.03)
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
PR Newswire - Thu Aug 06, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the second quarter 2015. IMUC: 0.48 (+0.03)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 3.02 (-0.06), CERU: 3.03 (-0.27), AMGN: 157.62 (+3.12), LLY: 81.08 (-0.15), BIND: 4.70 (-0.05), GSK: 40.54 (+0.31), BMY: 65.56 (+0.54), IMUC: 0.48 (+0.03), AZN: 33.33 (+0.55), CYTR: 3.07 (-0.06), AVEO: 1.14 (-0.02), ABBV: 60.17 (+0.16), EXEL: 5.60 (+0.12), ARRY: 4.20 (-0.06)
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
PR Newswire - Thu Jul 23, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the second quarter 2015 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO. IMUC: 0.48 (+0.03)
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 6.2% (IMUC)
Comtex SmarTrend(R) - Wed Jul 15, 10:42AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 6.2% to $0.51 on 1.2x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 489,000 shares, vs. average volume of 423,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.1%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
IMUC: 0.48 (+0.03)
Active Equities to Watch in the Biotechnology Industry -- Prima Biomed, Oncothyreon, Opko Health, ImmunoCellular Therapeutics, and Adaptimmune Therapeutics
PR Newswire - Wed Jul 15, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). Free research report on Prima Biomed can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PBMD On Tuesday, July 14, 2015, the NASDAQ Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial Average advanced 0.42%, to finish the day at 18,053.58, and the S&P 500 closed at 2,108.95, up 0.45%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PBMD: 1.12 (-0.02), OPK: 10.74 (+0.11), ADAP: 9.78 (+0.26), IMUC: 0.48 (+0.03), ONTY: 3.30 (-0.05)
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
PR Newswire - Mon Jul 06, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. The ICT-107 phase 3 trial will include approximately 120 clinical sites in the US, Europe and Canada, and will recruit about 400 patients with newly diagnosed glioblastoma. ImmunoCellular anticipates initiating the phase 3 trial in the fourth quarter of 2015. IMUC: 0.48 (+0.03)
Global Cancer Vaccines Market 2015-2019 with Dendreon, GSK & Merck Dominating
M2 - Tue Jun 30, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wtt7gg/global_cancer) has announced the addition of the "Global Cancer Vaccines Market 2015-2019" report to their offering. The global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019. Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines. Strategic alliances not only help a vendor increase its market penetration but they also enhance the vendor's product portfolio. For instance, GAVI Alliance aims to immunize about 2-million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are supplied at a low cost by GlaxoSmithKline and Merck. In 2015, Bristol-Myers Squibb collaborated with Bavarian Nordic to develop Prostvac, a therapeutic vaccine for the treatment of prostate cancer. Together, in 2015, Advaxis and Incyte evaluated ADXS-HPV using Incyte's investigational oral indoleamine 2,3-dioxygenase 1 inhibitor, epacadostat. In 2014, Boehringer Ingelheim and CureVac entered into an agreement to develop and commercialize a lung cancer vaccine CV9202 using CureVac's RNA technology, RNActive. According to the report, cancer is a leading cause of deaths worldwide. According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers. Further, the report states that cold chain, or temperature-controlled supply chain, management is a major challenge for this market. Key Vendors - Dendreon - GlaxoSmithKline - Merck Other Prominent Vendors - Aduro BioTech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Amgen - Antigen Express - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Bristol-Myers Squibb - Cytos - Galena Biopharma - Genexine - GlobeImmune - ImmunoCellular Therapeutics - Immutep - Inovio Pharmaceuticals - Isa Pharmaceuticals - Juvaris Biotherapeutics - MedImmune - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Progenics - Provectus Biopharmaceuticals - Sanofi - Sotio - Transgene - Ubivac For more information visit http://www.researchandmarkets.com/research/wt...bal_cancer
PVCT: 0.46 (-0.03), INO: 6.82 (-0.12), ARGS: 3.95 (-0.08), NWBO: 4.44 (+0.01), ADRO: 28.65 (+1.02), MRK: 53.66 (-0.04), NLNK: 35.26 (-0.74), AMGN: 157.62 (+3.12), GALE: 1.47 (unch), GSK: 40.54 (+0.31), BMY: 65.56 (+0.54), IMUC: 0.48 (+0.03)
